Generic Drug Sector Gets Better Information on API Manufacturing Costs from
Thomson Reuters and Rondaxe Enterprises

    


    
</pre>
<p><span class="xn-location">PHILADELPHIA</span> and <span class="xn-location">LONDON</span>, <span class="xn-chron">Sept. 1</span> /CNW/ -- Thomson Reuters and Rondaxe Enterprises today announced an agreement that will enable professionals working in the generic drug sector to better estimate the cost of manufacturing active pharmaceutical ingredients (API).</p>
<p/>
<p>Information on the costs associated with manufacturing APIs is vital for generic drug companies and API manufacturers around the world, which operate in an intensely price competitive market. Choosing the right drugs to develop and launch is imperative and can determine the difference between profitable or unprofitable products.</p>
<p/>
<p>Under the terms of the arrangement, patent and synthesis route data from Thomson Reuters will be combined with leading cost-of-goods (CoG) modeling tools from Rondaxe. This will allow professionals working in portfolio selection, research and development, as well as process chemists and engineers, to model drug manufacturing processes and to perform cost analysis simulations.</p>
<p/>
<p>"We are delighted to partner with Rondaxe to strengthen our services to the generic and API manufacturing market," said <span class="xn-person">Claude Bassett</span>, vice president of Specialty Markets at Thomson Reuters. "The partnership enables us to meet a demand from our clients for greater insight into the costs associated with manufacturing an API, which are often the most significant factor in the cost of goods of the finished generic drug."</p>
<p/>
<p><span class="xn-person">Ken Shultis</span>, CEO at Rondaxe Enterprises said; "We are excited to bring together our cost-of-goods expertise, augmented by our CoGs software product, with the leading information from Thomson Reuters in order to benefit pharmaceutical and biotech companies around the world."</p>
<p/>
<p>Customers using the Newport suite of products from Thomson Reuters will be able to request cost analyses from Rondaxe directly within the product.</p>
<pre>
    

    For more information about the Newport line of products, please visit:
    http://go.thomsonreuters.com/globalgenerics


    About Thomson Reuters
    
</pre>
<p>Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in <span class="xn-location">London</span> and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.  For more information, go to <a href="http://www.thomsonreuters.com">www.thomsonreuters.com</a>.</p>
<pre>
    

    About Rondaxe Enterprises
    
</pre>
<p>Rondaxe Enterprises is a unique company providing a suite of services that combines expert drug development consulting, in-depth project management leadership, software applications and virtual business development designed specifically for emerging pharmaceutical and biotech companies. Rondaxe is led by four managing members, a team of experienced industry executives and more than 50 senior advisors, most of whom have 15-30 plus years of industry experience, with a vision and an unflinching dedication to clients' success. Founded in 2003, Rondaxe has enjoyed steady growth based on a proven track record in delivering results, establishing solid relationships with customers, and a strong commitment to expand skills and product offerings as customer's needs expand.</p>
<pre>
    




    

For further information: Paul Sandell, [phone], [email protected] Web Site: http://www.thomsonreuters.com